Stock Events

Stock Events

Century Therapeutics 

$2.09
18
-$0.02-0.95% Thursday 20:00
+$0.00+0%Thursday 23:30After hours

Statistics

Day High
2.09
Day Low
2.08
52W High
3.04
52W Low
0.435
Volume
12,975
Avg. Volume
-
Mkt Cap
378.45M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.41
0.02
0.46
0.89
Expected EPS
-0.12
Actual EPS
N/A

Financials

-8.78%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
109.16MRevenue
-9.58MNet Income

Analyst Ratings

6.50Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IPSC. It's not an investment recommendation.
NVIDIA
7
NVDA
Palantir Technologies
6
PLTR
Apple
5
AAPL
Microsoft
5
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leading company in the gene editing space, directly competing with Century Therapeutics in developing gene-edited cell therapies for various diseases.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing field, making it a direct competitor to Century Therapeutics in the development of gene-edited therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, competing with Century Therapeutics in creating precise gene editing therapies.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is focused on allogeneic CAR T cell therapies, competing with Century Therapeutics in the field of cell therapy for cancer.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, making it a competitor in the cell therapy space alongside Century Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy arena, particularly in CAR T cell therapies, posing competition to Century Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, competing with Century Therapeutics in the broader gene therapy market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its investments in gene therapy and cell therapy, including partnerships and acquisitions, competes in the same therapeutic areas as Century Therapeutics.

About

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Show more...
CEO
Brent Pfeiffenberger
Employees
78
Country
United States
ISIN
US15673T1007

Listings

XNAS
US
IPSC
BOATS
BOATS
IPSC.BOATS

0 Comments

Share your thoughts

FAQ

What is Century Therapeutics stock price today?▼
The current price of IPSC is $2.09 USD — it has decreased by -0.95% in the past 24 hours. Watch Century Therapeutics stock price performance more closely on the chart.
What is Century Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Century Therapeutics stocks are traded under the ticker IPSC.
Is Century Therapeutics stock price growing?▼
IPSC stock has risen by +3.21% compared to the previous week, the month change is a +3.98% rise, over the last year Century Therapeutics has showed a +336.51% increase.
What is Century Therapeutics market cap?▼
Today Century Therapeutics has the market capitalization of 378.45M
When is the next Century Therapeutics earnings date?▼
Century Therapeutics is going to release the next earnings report on November 05, 2026.
What were Century Therapeutics earnings last quarter?▼
IPSC earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.11 USD resulting in a -54.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Century Therapeutics revenue for the last year?▼
Century Therapeutics revenue for the last year amounts to 109.16M USD.
What is Century Therapeutics net income for the last year?▼
IPSC net income for the last year is -9.58M USD.
How many employees does Century Therapeutics have?▼
As of September 04, 2026, the company has 78 employees.
In which sector is Century Therapeutics located?▼
Century Therapeutics operates in the Health & Wellness sector.
When did Century Therapeutics complete a stock split?▼
Century Therapeutics has not had any recent stock splits.
Where is Century Therapeutics headquartered?▼
Century Therapeutics is headquartered in PHILADELPHIA, United States.